X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding aims to focus on the clinical development of their product SM07883, which is a DYRK1A inhibitor. Currently, it is being evaluated in preclinical trial studies for the treatment of Tauopathies including Alzheimer's Disease and Frontotemporal Dementia.
Lead Product(s): SM07883
Therapeutic Area: Neurology Product Name: SM07883
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roskamp Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding March 08, 2024
Details:
Results from the study continue to support the potential efficacy of multiple injections of SM04690 (lorecivivint) in delaying structural progression and providing symptomatic benefic.
Lead Product(s): Lorecivivint
Therapeutic Area: Immunology Product Name: SM04690
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
SM04690 (lorecivivint), demonstrated clinical efficacy in earlier, less structurally damaged patients, although these trials fell short of reaching statistical significance in their primary endpoints of Pain NRS (daily pain score) at week 12 with all subjects.
Lead Product(s): Lorecivivint
Therapeutic Area: Immunology Product Name: SM04690
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
Details:
Cirtuvivint (SM08502) is a small-molecule inhibitor of the CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation-regulated (DYRK) kinases that are emerging as key contributors to numerous forms of cancer.
Lead Product(s): Cirtuvivint
Therapeutic Area: Oncology Product Name: SM08502
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2022
Details:
Cirtuvivint is a small-molecule inhibitor of the CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation-regulated (DYRK) kinases that are emerging as key contributors to numerous forms of cancer.
Lead Product(s): Cirtuvivint,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: SM08502
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2021
Details:
Lorecivivint has showed structural benefit, as measured by X-ray analysis of medial joint space width, 52 weeks following a single injection in the target knee. Lorecivivint has appeared safe and well-tolerated in studies to date.
Lead Product(s): Lorecivivint
Therapeutic Area: Musculoskeletal Product Name: SM04690
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Haisco Pharmaceutical
Deal Size: $140.0 million Upfront Cash: $20.0 million
Deal Type: Licensing Agreement September 15, 2021
Details:
Biosplice showed that study subjects dosed with 0.07 mg lorecivivint were over two times more likely to meet the criteria for OMERACT-OARSI Strict Response, a measure that includes 50% improvement in pain or function, than those on placebo at 12 weeks.
Lead Product(s): Lorecivivint
Therapeutic Area: Musculoskeletal Product Name: SM04690
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2021
Details:
In this 24-week clinical trial, Biosplice’s groundbreaking knee OA drug candidate, lorecivivint, met primary endpoints of Pain NRS (daily pain measurement) at both 12 and 24-week timepoints.
Lead Product(s): Lorecivivint
Therapeutic Area: Musculoskeletal Product Name: SM04690
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2021
Details:
Lorecivivint (SM04690) is currently being evaluated in Phase 3 pivotal trials for the treatment of knee osteoarthritis in the United States. Samil will lead development, regulatory and commercialization activities for lorecivivint in the Republic of Korea.
Lead Product(s): Lorecivivint
Therapeutic Area: Musculoskeletal Product Name: SM04690
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Samil Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
